Any Port in a Storm: Vessel Activity and the Risk of IUU-Caught Fish Passing through the World’s Most Important Fishing Ports

This study assesses the risk of fish from illegal, unregulated and unreported (IUU) sources passing through the world’s most important fishing ports and explores the drivers of this risk. Like previous studies it has attempted to rank ports and States based on landings and vessel visits reported by governments by using Automatic Identification System (AIS) positional data transmitted by fishing and fish carrier vessels to identify the locations of ports and rank them based on the frequency of visits by foreign-flagged and domestic-flagged vessels. It advances our thinking in that (i) the analysis includes an estimation of the hold capacity of fishing vessels and is therefore able to rank ports based on the total hold capacity of vessels visiting them and (ii) the profile and the frequency of vessel visits inform an assessment of the relative risks between different ports, and the implications for the implementation of the Port State Measures Agreement (PSMA). The study also assesses the accuracy and utility of AIS-derived data for determining IUU risk globally for all ports, notably by cross-referencing its findings with those of other studies. The study develops a broad suite of indicators that quantify and aggregate the AIS-derived port visit information in conjunction with published and publicly available policy and regulatory information drawn from other sources, such as the compliance record with binding port State measures of regional fisheries management organizations, to raise a global port State IUU Risk Index. The comparison of achieved risk scores with national income, levels of corruption, and geography provides insights into factors driving (aggravating) or modulating (mitigating) risks of IUU-caught seafood passing through a Nation’s fishing ports, and supports a view that States with weaker governance also face higher odds of visits by vessels likely to have engaged in IUU fishing (i.e. higher external risks). Based on an in-depth assessment of 14 individual ports globally, appended as a supplement to this paper, the study finds that overall, and with the possible exception of mandatory advance request procedures for entering ports, the implementation of key provisions of the 2009 PSMA remains severely lacking. The two main areas for improvement are the posting of publicly available PSM-related information on national and/or FAO portals, and the formal designation of ports

TRAF4 is a novel phosphoinositide-binding protein modulating tight junctions and favoring cell migration

Tumor necrosis factor (TNF) receptor-associated factor 4 (TRAF4) is frequently overexpressed in carcinomas, suggesting a specific role in cancer. Although TRAF4 protein is predominantly found at tight junctions (TJs) in normal mammary epithelial cells (MECs), it accumulates in the cytoplasm of malignant MECs. How TRAF4 is recruited and functions at TJs is unclear. Here we show that TRAF4 possesses a novel phosphoinositide (PIP)-binding domain crucial for its recruitment to TJs. Of interest, this property is shared by the other members of the TRAF protein family. Indeed, the TRAF domain of all TRAF proteins (TRAF1 to TRAF6) is a bona fide PIP-binding domain. Molecular and structural analyses revealed that the TRAF domain of TRAF4 exists as a trimer that binds up to three lipids using basic residues exposed at its surface. Cellular studies indicated that TRAF4 acts as a negative regulator of TJ and increases cell migration. These functions are dependent from its ability to interact with PIPs. Our results suggest that TRAF4 overexpression might contribute to breast cancer progression by destabilizing TJs and favoring cell migration

Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease

BACKGROUND: Patients with atherosclerotic vascular disease remain at high risk for cardiovascular events despite effective statin-based treatment of low-density lipoprotein (LDL) cholesterol levels. The inhibition of cholesteryl ester transfer protein (CETP) by anacetrapib reduces LDL cholesterol levels and increases high-density lipoprotein (HDL) cholesterol levels. However, trials of other CETP inhibitors have shown neutral or adverse effects on cardiovascular outcomes. METHODS: We conducted a randomized, double-blind, placebo-controlled trial involving 30,449 adults with atherosclerotic vascular disease who were receiving intensive atorvastatin therapy and who had a mean LDL cholesterol level of 61 mg per deciliter (1.58 mmol per liter), a mean non-HDL cholesterol level of 92 mg per deciliter (2.38 mmol per liter), and a mean HDL cholesterol level of 40 mg per deciliter (1.03 mmol per liter). The patients were assigned to receive either 100 mg of anacetrapib once daily (15,225 patients) or matching placebo (15,224 patients). The primary outcome was the first major coronary event, a composite of coronary death, myocardial infarction, or coronary revascularization. RESULTS: During the median follow-up period of 4.1 years, the primary outcome occurred in significantly fewer patients in the anacetrapib group than in the placebo group (1640 of 15,225 patients [10.8%] vs. 1803 of 15,224 patients [11.8%]; rate ratio, 0.91; 95% confidence interval, 0.85 to 0.97; P=0.004). The relative difference in risk was similar across multiple prespecified subgroups. At the trial midpoint, the mean level of HDL cholesterol was higher by 43 mg per deciliter (1.12 mmol per liter) in the anacetrapib group than in the placebo group (a relative difference of 104%), and the mean level of non-HDL cholesterol was lower by 17 mg per deciliter (0.44 mmol per liter), a relative difference of -18%. There were no significant between-group differences in the risk of death, cancer, or other serious adverse events. CONCLUSIONS: Among patients with atherosclerotic vascular disease who were receiving intensive statin therapy, the use of anacetrapib resulted in a lower incidence of major coronary events than the use of placebo. (Funded by Merck and others; Current Controlled Trials number, ISRCTN48678192 ; ClinicalTrials.gov number, NCT01252953 ; and EudraCT number, 2010-023467-18 .)

Presentation: Women Professionals in Architecture, Law and Medicine

Kay Standley and Dr. Bradley Soule, Women Professionals in Architecture, Law and Medicine Kay Standley and Dr. Bradley Soule, a psychologist and a psychiatrist from Washington, D.C., have recently completed a study dealing with professional women in the fields of law, medicine, and architecture, under the auspices of the National Institute of Child Health and Human Development. They have previously presented this study to the A.W.A. in New York. Kay Standley received her A.B., M.A.Ed. and Ph.D. at Washington University. Bradley Soule completed his undergraduate work at Amherst College and received his M.D. at the University of Vermont. Both have written numerous papers on professional women and have contributed publications to journals including The American Bar Association Journal and The Journal of Vocational Behavior

Panel Discussion: Role Problems Facing Professional Women

Panel: Role Problems Facing Professional Women Panelists: Whitney Gordon, Gertrude Kerbis, Kay Standley, Bradley Soule, and Leslie Weisman Moderator: Judith Edelman Leslie Weisman is Professor of Architecture at the University of Detroit. She is also currently Director of Admissions and Area Coordinator for Communications Design in the School of Architecture and Environmental Studies. Ms. Weisman has an undergraduate degree in Fine Arts. She received her graduate degree from the University of Detroit in Urban Studies. Ms. Weisman recently initiated a study entitled The Effects of the Predominantly Male Architectural Academic Environment upon the Self-image of the Female Architecture Students

Any Port in a Storm: Vessel Activity and the Risk of IUU-Caught Fish Passing through the Worlds Most Important Fishing Ports

This study assesses the risk of fish from illegal, unregulated and unreported (IUU) sources passing through the world's most important fishing ports and explores the drivers of this risk.Like previous studies it has attempted to rank ports and States based on landings and vessel visits reported by governments by using Automatic Identification System (AIS) positional data transmitted by fishing and fish carrier vessels to identify the locations of ports and rank them based on the frequency of visits by foreignflagged and domestic-flagged vessels. It advances our thinking in that (i) the analysis includes an estimation of the hold capacity of fishing vessels and is therefore able to rank ports based on the total hold capacity of vessels visiting them and (ii) the profile and the frequency of vessel visits inform an assessment of the relative risks between different ports, and the implications for the implementation of the Port State Measures Agreement (PSMA). The study also assesses the accuracy and utility of AIS-derived data for determining IUU risk globally for all ports, notably by cross-referencing its findings with those of other studies.The study develops a broad suite of indicators that quantify and aggregate the AIS-derived port visit information in conjunction with published and publicly available policy and regulatory information drawn from other sources, such as the compliance record with binding port State measures of regional fisheries management organizations, to raise a global port State IUU Risk Index. The comparison of achieved risk scores with national income, levels of corruption, and geography provides insights into factors driving (aggravating) or modulating (mitigating) risks of IUU-caught seafood passing through a Nation's fishing ports, and supports a view that States with weaker governance also face higher odds of visits by vessels likely to have engaged in IUU fishing (i.e. higher external risks).Based on an in-depth assessment of 14 individual ports globally, appended as a supplement to this paper, the study finds that overall, and with the possible exception of mandatory advance request procedures for entering ports, the implementation of key provisions of the 2009 PSMA remains severely lacking. The two main areas for improvement are the posting of publicly available PSM-related information on national and/or FAO portals, and the formal designation of ports

An augmented computer model of motor unit reorganization in neurogenic diseases of skeletal muscle

A computer model of denervation and complete reinnervation in skeletal muscle was originally developed for the purpose of furthering an understanding of the underlying mechanisms of motor unit reorganization in neurogenic diseases. We now describe its successor, a computer model for investigating different rates of denervation and reinnervation, as well as incomplete reinnervation. The new model introduces the concept of permanent denervation and features enhanced interactive control over the distribution of motor unit centers and additional measures of dispersion and co‐dispersion of muscle fibers. The use of this model for investigating pathophysiologically significant issues in denervating diseases is illustrated pathophysiologically significant issues in denervating diseases is illustrated with five different sets of parameters. These simulate some of the processes that may be operational in chronic spinal muscular atrophy, amyotrophic lateral sclerosis, and progressive postpolio muscular dystrophy. The enhanced model will allow in‐depth analysis of the influence of hypothesized pathophysiological processes on clinical, electrophysiological and pathological outcomes in human disease. © 1993 John Wiley & Sons, Inc

Quantitative morphometric study of muscle in inclusion body myositis

Clinical and electromyographic findings do not clearly distinguish body myositis (IBM) from chronic polymyositis (PM). The rimmed vacuoles and filamentous nuclear and cytoplasmic inclusions that characterize IBM are often sparse and may be overlooked; conversely, these features may occasionally be seen in other diseases. Preliminary studies suggested that muscle fiber hypertrophy occured more frequently in IBM than in PM. To investigate whether fiber hypertrophy can be used to improve the ability to separate IBM from PM, we report a morphometric analysis of 28 IBM cases, 22 PM and 22 dermatomyositis (DM) cases. The analysis, using a computer automated system, included proportion of hypertrophied fibers and also fiber type proportions, average fiber diameter, proportion of atrophic and angulated fibers, and the co-dispersion index (CDI). The proportion of hypertrophied fibers was greater in IBM than the other two conditions (IBM(mean ± SEM) 31.0 ± 4.7% and 12.2 ± 2.4% for type 1 and type 2 fibers, respectively, compared to 9.8 ± 3.0% and 3.3 ± 1.7% in PM, and 7.7 ± 2.7% and 3.9 ± 1.9% in DM). These differences were statistically significant (P < 0.05) in both sexes for type 1 fibers and in women for type 2 fibers. Also, the average fiber size and hypertrophy factors for type 1 and type 2 fibers were increased in IBM compared to PM and DM. This study confirms that the presence of muscle fiber hypertrophy in biopsies from IBM patients may help differentiate them from other clinically similar inflammatory myopathies